✦ LIBER ✦

A 24-week, open-label extension to the ACTivities of daily living and cognitION (ACTION) study: Long-term safety, tolerability and efficacy of a 13.3 mg/24 h rivastigmine patch in people with severe Alzheimer's disease

✍ Scribed by Farlow, Martin; Grossberg, George; Sadowsky, Carl; Meng, Xiangyi; Somogyi, Monique

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term safety and efficacy of 13.3mg/

✍ Farlow, M.; Grossberg, G.; Sadowsky, C.; Meng, X.; Somgyi, M. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Efficacy, safety and tolerability of riv

✍ Farlow, Martin; Meng, Xiangyi; Rensch, Scott; Somogyi, Monique 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Efficacy, safety and tolerability of riv

✍ Farlow, Martin; Meng, Xiangyi; Somogyi, Monique 📂 Article 📅 2013 🏛 American Psychiatric Publishing Inc 🌐 English ⚖ 61 KB

Efficacy, safety and tolerability of a h

✍ Grossberg, George; Farlow, Martin; Meng, Xiangyi; Somogyi, Monique 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Effect of body mass index on the efficac

✍ Sadowsky, Carl; Somogyi, Monique; Frolich, Lutz; Meng, Xiangyi 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 53 KB

P.4.006 Long-term efficacy and safety be

✍ H.-J. Moebius; B. Reisberg; F. Schmitt; R. Doody 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 274 KB